Breast magnetic resonance imaging (MRI) screening of women under 50 years old at high familial risk of breast cancer was given interim funding by Medicare in 2009 on the basis that a review would be undertaken. An updated literature review has been undertaken by the Medical Services Advisory Committee but there has been no assessment of the quality of the screening or other screening outcomes. This review examines the evidence basis of breast MRI screening and how this fits within an Australian context with the purpose of informing future modifications to the provision of Medicare-funded breast MRI screening in Australia. Issues discussed will include selection of high-risk women, the options for MRI screening frequency and measuring the outcomes of screening.
Introduction
Around 1 in 800 1 women in the Australian population are estimated to have an inherited mutation in a cancer predisposition gene, and significantly more with a strong family history but no known familial mutation, are at high risk of breast (and other) cancer(s). Women at high risk of breast cancer, with or without a known genetic mutation, have multiple strategies available to them for managing their elevated cancer risk. Risk-management options include bilateral mastectomy, risk-reducing medication and screening programs which comprise of clinical assessment and mammography +/À breast magnetic resonance imaging (MRI). Although it is the most sensitive imaging technique for cancer detection [2] [3] [4] [5] [6] [7] [8] [9] (Figs. 1-4), breast MRI can only be included if a woman meets the Medicare Benefits Schedule (MBS) criteria for access to this test or decides to pay for this imaging herself. MRI is almost always combined with mammography to maximise the detection of breast malignancy otherwise some cancers will be missed.
In 2009 the Australian Government funded breast MRI for 'the diagnosis of breast cancer in asymptomatic women with a high risk of developing breast cancer when used as part of an organised surveillance program.' The eligibility criteria for screening provide for an annual breast MRI for women under 50 years with a known mutation predisposing to breast cancer (BC) or those women who fit the 'National Breast and Ovarian Cancer Centre (NBOCC) Category 3' risk (estimated to approximate to >25% lifetime risk), 1 plus a follow up MRI 6 months later if needed. The MBS-funded item was introduced with a proviso that a review would be undertaken. Only an updated literature review has occurred and there are no official plans by Medicare to undertake a review of the performance and/or outcomes of breast MRI screening.
We have sparse data on the outcomes of breast MRI screening in these younger women at high familial breast cancer risk in Australia as they do not fit within any current population breast screening programme and outcomes such as sensitivity, specificity and interval cancer rates are not routinely or consistently recorded. Data from international breast MRI screening studies (not out-of-trial, or 'real-life', MRI screening environments) suggest that these outcome parameters are at least comparable to population mammographic screening programs of women >50 years. [2] [3] [4] [5] [6] [7] [8] [9] Although there is some evidence for down staging of MRI-detected tumours both in terms of tumour size and lymph node status at diagnosis, any improvement in breast cancerspecific survival data is yet to be seen.
2-9
Developing a breast cancer risk management plan with an individual woman at high risk can be complex, depending on their level of risk, availability of resources, personal preference and the current limits of scientific knowledge. Any or a combination of these factors can provide barriers to appropriate care of women with a high lifetime risk of breast cancer.
The aim of this article is to present a review regarding the important issues surrounding MRI breast screening that remain in Australia. We will highlight the areas of controversy that provide challenges in daily clinical practice and the limitations of the available evidence in support of breast MRI screening.
Defining Breast Cancer Risk
The first challenge to the evidence-based management of women at high risk of breast cancer is the inconsistency in the medical literature regarding the definition of 'high risk'. Traditionally 'high risk' in the Australian context has been defined as a ≥25% lifetime risk 1 whereas, in contrast, some international screening studies have considered high risk to be ≥20%. 9 Breast cancer risk for the purposes of cancer screening or prevention research and/or clinical practice, has tended to be considered as either an inherited form of risk (genetic or 'familial' risk) category or a personal risk factor-based risk category focused on the presence or absence of personal breast cancer risk or protective factors and the incorporation of familial risk factors in the latter category is highly variable in its detail.
There are a number of methods or risk calculators available to determine genetic or 'familial risk'. 10, 11 Historically risk has been calculated by Claus tables, 12 which provide an estimate of breast cancer risk based on a woman's current age and the number, and ages of onset, of breast cancers in close relatives. These tables are based on empiric observational data and make limited assumptions about the genetic basis of the family history and therefore of cancer risk in close relatives. They are easy to apply in the clinical setting but have limitations to their use including reduced utility in paternally inherited risk and in small sized families, and lack of integration of family structure and other personal breast cancer risk factors.
A commonly used personal risk factor-based risk calculator that does take into account a range of risk factors is the Breast Cancer Risk Assessment Tool (BCRAT, previously known as the Gail model). 13 The BCRAT includes demographics such as age and race, family history, presence of benign breast disease and certain hormonal factors. It was initially derived from a Caucasian population undergoing routine mammographic screening but has been updated and is calibrated for women of African, 14 Pacific Islander and Asian descent. 15 Its strength lies in that it takes into account more factors than just family history. However, it does not discriminate between levels of genetic risk as accurately as some of the other calculators. The family history included is limited to the first generation and age of cancer diagnosis is not included and therefore is best suited to women who approximate to the general population and is not well suited to women who have a strong family history of breast cancer. Recently, more comprehensive risk calculators have been developed for women with a suspected genetic or familial breast cancer risk, such as the Tyrer-Cuzick model 16 (IBIS Breast Cancer Risk Evaluation Tool) and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) 17 tools. Both models have a more sophisticated approach to determining genetic risk than Claus tables or BCRAT but also include risk factors other than family history. They vary in the fine details regarding the method and weight of incorporation of personal risk factors (such as age of menarche) and tumour pathology features to the estimate of breast cancer risk, and in their overall ease of use. BOADICEA has a more complex user interface and is currently more suited to the genetics clinic environment rather than being designed for daily use in other clinical settings where these women are most often managedthat is surveillance breast clinics, specialists' rooms or general practice. In contrast, the IBIS tool was developed from risk factor data derived from women participating in the IBIS breast cancer prevention studies and includes multiple non-genetic risk factors such as biomorphic markers and benign breast disease. It is administered as a single Web page data collection form and is generally more well-suited to a busy clinical setting that BOADICEA. Family history is a major component of the IBIS tool risk calculation but it uses more broad familial risk categories than BOADICEA and therefore may not gradate genetic risk as well as BOADICEA.
As the selection and use of risk calculators is a relatively complex undertaking and can be perceived as time-consuming for a busy clinical practice, in 2006 the Medical Services Advisory Committee (MSAC) advised the use of NBOCC Category 3 (as described in Table 1) as the definition of high risk for the purposes of determining eligibility for MRI screening. While this category is designed to capture women who have >25% lifetime risk of breast cancer, it is still a broad category and risks including women with significantly lower lifetime risks (especially if they have large families with multiple female relatives) and also excluding women with >25% lifetime risk, often as a result of a paternal inheritance pattern of risk or having a small family with few at-risk female relatives.
Internationally, criteria for inclusion in breast MRI clinical screening programs and/or research studies for 18 demonstrated using three commonly used risk prediction models that there was minimal agreement for which individual women were at high risk. In that study, a retrospective analysis of 10,000 women who received mammographic screening was performed. The lifetime risk of developing breast cancer using the BRCAPRO, Claus, and Tyrer-Cuzick calculators was then calculated and eligibility for breast MRI screening was defined as a lifetime risk ≥20%. The percentage of women found to be eligible for MRI screening by the Tyrer-Cuzick model was 5.6%, by BRCAPRO was 0.4% and by the Claus model was 0.9%. Only 0.2% of the study population was eligible by all three risk models.
Women at High Risk of Developing Breast Cancer for Reasons Other Than High Genetic or Familial Risk
As well as women at high genetic or familial risk of breast cancer, other groups of women can also be recognised as having a significant lifetime risk of developing breast cancer. However, whether or not any of these groups would benefit from the addition of routine breast MRI screening is poorly studied, if at all.
Women treated with chest irradiation prior to age 30 years are at particularly high risk of developing breast cancer, 19 and this risk can approximate to that associated with a BRCA1 or BRCA2 mutations in some cases. A number of published guidelines (including the American Cancer Society, 20 NCCN 21 and The UK National Breast Cancer Screening Programme 22 ) recommend breast MRI screening for women who received therapeutic chest irradiation; combined with mammography this has been found to have a sensitivity of 94%. 23 However, after their recent literature review the MSAC in Australia have decided that the evidence is not yet clear enough to expand the eligibility criteria for Medicare-funded breast MRI screening to include women who received therapeutic chest irradiation for lymphoma as young women.
It is also recognised that women with a prior history of a range of benign breast lesions have a significant increased breast cancer risk. 24 For example women with atypical ductal hyperplasia have been found to have a relative risk of 4.24. 25 For women diagnosed with lobular carcinoma in situ (LCIS) the risk is similar in magnitude to women with a BRCA 1 or 2 mutation. 26 It is not known if the addition of breast MRI to mammographic and or ultrasound screening improves outcomes for women with LCIS.
Women with mammographically dense breasts are another subgroup with an increased risk of breast cancer , an effect which is compounded by the fact increased breast density reduces the sensitivity of mammography for detecting breast cancers. [27] [28] [29] [30] [31] [32] [33] In 2014, in the United States Congress a bill has been introduced that makes reporting of breast density on mammograms mandatory and has variably been introduced into State legislation across the United States. 34 A recent study 35 reviewing the addition of ultrasound in women with high mammographic density found that the risks did not outweigh the benefits, however, some novel mammographic techniques such as digital tomosynthesis or molecular imaging are currently being investigated in these women as useful adjuncts to mammography.
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Breast MRI Screening Frequency and Scheduling
For women at high genetic or familial risk, the optimal breast cancer screening frequency is still to be determined. If left too long then there is the risk of interval cancers, but if screening is too frequent then cost effectiveness is reduced. Most clinicians recommend starting screening at 25-30 years or 10 years before the youngest relative developed breast cancer. The current Australian Medicare scheme only provides a rebate for breast MRI screening in women under 50, but clearly for some this arbitrary age limit may not be applicable as evidenced by a recently published meta-analysis of the data for BRCA mutation carriers over 50.
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Another area of uncertainty is the scheduling of breast MRI screening with mammography with some guidelines advising concurrent imaging and others alternating breast MRI with mammography every 6 months. 42, 43 The attraction of an alternating approach is the possibility of minimising the occurrence of interval cancers (Figs. 5 and 6), but that assumes that both tests are sensitive in detecting breast cancer and it is clear that mammography is much less sensitive than MRI in detecting invasive breast cancer. Furthermore, the practical considerations of scheduling a menstruation-based test and alternating this with another test on a frequent basis, in women with busy professional and family lives, are important and certainly can be challenging and potentially risk compromising screening frequencies. Recently published data suggests that routine mammography in the setting of breast MRI screening may be superfluous. Traditionally mammograms were included in the screening schedule with MRI as initial MRI screening studies suggested mammograms remained the preferred screening test for detecting DCIS. to increasing grade of DCIS (whereas mammographic sensitivity is inversely proportional) 45 but with increasing reader experience it is also more sensitive overall than mammography. [46] [47] [48] [49] A recent study 50 of 559 women found that despite two cases of DCIS being found by mammography alone, there was no improvement in sensitivity with the addition of mammography (or ultrasound).
Performance of Breast MRI Screening in High-Risk Women
The point of screening is to reduce mortality from the disease of interest by early detection. Certain principles need to apply for this to be successful. First, the screening population needs to be strictly defined and there needs to be a scientific body of evidence proving that the screening of choice is effective. Second, a set of agreed quality assurance criteria and performance measures against which outcomes can be audited and benchmarked are necessary to ensure that effectiveness is maintained.
Breast MRI screening in Australia for women at high genetic or familial risk fulfils some of these criteria Unfortunately, the population defined as eligible for screening in Australia differs from most other countries which use a risk calculator derived lifetime risk score as previously discussed. A comparison between these guidelines can be seen in Table 2 . Unlike organised mammographic screening in Australia, there are no Australian national quality performance indicators for MRI screening, and no co-ordinated data collection or regular formal quality assurance audit occur. This is especially important with MRI screening as imaging findings can be subtle (Figs. 7-10 ) and false positives are not uncommon. The addition of breast MRI screening to mammography in the management of high-risk women results in significantly increased sensitivity (up to 94% 5,51 ) compared to 40% for mammography alone, an increase in the proportion of node-negative cancers diagnosed compared to mammography alone (70-83% 5 ) as well as a projected 25% mortality benefit, 52 which provides high-risk women with a reasonable alternative risk-management strategy to surgery (bilateral mastectomy). However the relevant literature on which MBS funding was based, 2,5,8,9,53-59 comprised of nonrandomised cohort studies with significant heterogeneity of inclusion criteria and definition of outcome measures. In addition although there are abundant data that MRI screening improves screening outcomes such as the cancer detection rate, there is no evidence yet that it improves survival from the disease. Given the use of cohort study design, researchers have not been able to fully address concerns about the potential for oversensitivity-, lead time bias and overdiagnosis with breast MRI screening. A randomised, controlled trial of mammography alone versus an MRI-based strategy is now highly unlikely in this high-risk population to address many of these issues. This is due to a lack of clinical equipoise in managing these patients with mammography alone as well as the lack of appetite of high-risk women to be randomised to mammography alone.
Until now this article has considered women at high genetic or familial risk as a single homogeneous group, but in reality within this group there is a range of level of personal risk and it is likely that the utility of addition of MRI to a screening program will vary with level of risk. The benefit of the addition of breast MRI screening for women at risk is most equivocal for women with no known mutation in a cancer predisposition gene. Six major studies 2,5,9,53-55 included women without known mutations and were recruited on the basis of their breast cancer family history. The most recent of these studies 53 is potentially the most informative due to the increased experience of their radiologists in the interpreting of breast MRIs compared with older studies, as well as inclusion criteria that use the more discriminating breast cancer risk calculators (lifetime risk ≥25% using BOADICEA or IBIS). The cancer detection rate of MRI with mammography in patients with a mutation was 30.8/1000 initial screening examinations as opposed to 6.9/1000 initial screening examinations in those without; this difference was statistically significant. To put some context around these figures, in Australia, the population-based mammographic screening program, Breastscreen, detected 10.4 cancers/1000 initial screening examinations; 60 this figure includes all women aged 50-69 years, so is a composite of women at a range of personal cancer risks. The rate of 6.9/1000 was observed in younger women than those attending Breastscreen (over half were younger than 50 years at the time of screening).
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A specific area of uncertainty unique to Australia is the heterogeneity of practice caused by the interpretation of the MBS descriptor with respect to a woman's eligibility for breast MRI screening. Specifically, whether currently asymptomatic high-risk women who have a personal history of breast cancer are eligible for ongoing breast MRI screening once their breast cancer treatment is complete. Some screening studies included this population of women -for example three 9,53,55 of the six previously discussed studies included this group which made up 9.9, 27.9 and 30.8% of the study population, respectively, and thus it can be argued there is an evidence base for this practice.
An important question is whether the published breast MRI studies are relevant to the Australian population and in particular to the women eligible for breast MRI 
Measuring Breast MRI Screening Outcomes
Useful measures for assessing screening outcomes include the cancer detection rate, median size of invasive cancer, percentage of node-negative invasive cancers, percentage of invasive cancer ≤10 mm or DCIS, percentage of stage 0 or 1 cancer, recall rate, positive predictive value, sensitivity and specificity. The breast MRI screening studies performed to date do not report their outcomes against all of these indicators or choose one uniform outcome and thus it is difficult to compare outcomes across studies. Further increasing the difficulty in the interpretation of this data is that different studies may use the same indicator but use different ways of expressing its value. For example both Rjinsberger et al. 54 and Chiarelli et al. 53 use the outcome 'cancer detection rate' but the former define it per 1000 women years and the latter use per 1000 initial screening examinations.
Other outcomes can be difficult to interpret because the absolute number of events is low, for example the interval cancer rate has not been shown to be statistically significant between MRI and non-MRI screened groups but due to the small numbers of events it is not clear whether the interval cancer rate is truly not different between MRI and non-MRI screened groups. There is no agreed measure of outcomes of breast MRI screening in Australia and no facility in place to collect and/or monitor outcomes data, unlike the mandated measures evaluating the performance of Breastscreen.
Cost-Effectiveness of MRI Screening
Models of cost-effectiveness of incorporating breast MRI in screening schedules for high-risk women have supported the use of breast MRI screening in this group. 52, [61] [62] [63] [64] However, only three 52, 62, 64 used data that included women without mutations and only two of these 39, 51 analysed their data separately from known mutation carriers. Both the Dutch 52 (15-50% lifetime risk) and the American 64 (≥25% life time risk) costeffectiveness modelling studies found the most cost effective screening in non-mutation carriers would be staggered biennial MRI scans and mammograms. The relevance of these cost-effectiveness data to an Australian setting remains unknown as costs can differ significantly between countries and the data on which they are based were derived from studies undertaken in the early 2000s when breast MRI, and experience with it, was in its infancy and may now be outdated if the results from Kuhl et al are more representative of current practice and outcomes. We do know from a study of an Australian screening initiative run via a Familial Cancer Centre in Melbourne encompassing the years [2006] [2007] [2008] [2009] 65 that there is a significant financial and temporal burden in running an MRI Screening program in Australia. However, the costs may have changed since this time period. Additionally, increased staff experience over this time may now have ameliorated some of the issues described.
The additional benefit of MRI screening to routine mammography-based screening schedules appear to be greatest in women with the highest breast cancer risks and therefore restricting breast MR screening to this group should maximise the cost-effectiveness of breast MRI screening for healthcare systems. Just as important as cost-effectiveness are the negative consequences women can experience as a result of the screening. These include anxiety related both to the test and/or its results, inconvenience, discomfort and financial and other costs to the woman (such as travel, missing work, the costs of seeing a breast surgeon or other specialist(s)). Scans that are ultimately designated as false positive are particularly distressing as the woman undergoes the distress of a biopsy that was never needed and has to deal with the psychological consequences of anticipating a potential cancer diagnosis.
The number of women without a known mutation in a cancer predisposition gene accessing breast MRI screening in Australia and their screening outcomes are of great interest given that the cost-effectiveness of screening is highly dependent on the overall cancer detection rate. In one American study, 66 there was a significant an increase in Breast MRI use from 2000 to 2011 from 6.5/10,000 women to 104.8/10,000 of which 57.6% were for screening or surveillance. However, only 21% of these patients met local guidelines for screening and only 48.4% of women with documented genetic mutations were receiving MRI screening.
Other Screening Outcomes of Interest
In the 'quality of healthcare' literature six dimensions of care are defined. These are consumer participation, equitable access, effectiveness, efficiency, appropriateness and safety of care. The potential drawbacks of the high cost and oversensitivity of breast MRI screening are clear and are accentuated if inappropriate women (i.e., those not at high enough risk) are screened. It is essential that screening outcomes are investigated within different types of hospitals and different States to ensure they are equivalent. Furthermore, the use of additional investigations post-MRI should be carefully measured as the psychological effects of false-positive tests in women undergoing screening are well documented. [67] [68] [69] High false positive rates also challenge the cost-effectiveness equation for breast MRI screening for healthcare providers. While estimates of these items were addressed in the original screening studies, it is important to investigate whether cancer detection rates, false-positive rates, additional health care utilisation costs are different outside of the trial setting in order to inform the true cost-effectiveness of this intervention in the real-life setting.
Conclusions
The Screening Framework published by The Australian Population Health Development Principal Committee 70 maintains that 'there is an ethical obligation to maximise benefits and minimise harm; and the overall benefits should outweigh any harms that result from screening'. Clearly there is the potential that at present that a group of women in Australia is being over screened by breast MRI and other groups of high risk women are being denied breast MRI screening as their familial risk cannot be captured adequately using the current method incorporated within the MBS descriptor. Thus there is an urgent need to review both the performance of MRI Screening in Australia as well as the eligibility criteria for this test, to ensure that first, we do no harm.
